Lazard Announces Leadership Appointments in UK Investment Banking
9.9.2019 23:30:00 EEST | Business Wire | Press release
Lazard Ltd (NYSE: LAZ) announced today that it has named Cyrus Kapadia as Chief Executive Officer (CEO) of Lazard Investment Banking in the UK and William Rucker, CEO of the business since 2004, as Chairman, effective immediately. Archie Norman, Chairman of the business since 2013, will continue to serve Lazard as a Special Adviser to Lazard’s CEO.
“William has successfully built and led one of our firm’s most important investment banking franchises in his career at Lazard over the past 30 years,” said Kenneth M. Jacobs, Chairman and CEO of Lazard. “This transition will allow him to focus his efforts as a preeminent adviser to our UK clients.”
“Cyrus is an experienced and trusted adviser to clients, and has played a key role in the recruitment and retention of our people, as well as the evolution, technology advancements and diversification of our business in the UK,” said Peter Orszag, CEO of Lazard Financial Advisory. “In his new role, he will focus on the continued growth of our UK business and on achieving even closer cooperation globally on behalf of our clients.”
“Archie has made invaluable contributions to the firm as Chairman of UK Investment Banking for the past six years, and we thank him for all that he has accomplished,” said Mr. Jacobs. “We look forward to continuing to benefit from his sage advice.”
Mr. Kapadia, most recently Deputy Head of UK Investment Banking, joined Lazard in 1996. He has worked with clients across numerous industry sectors and leads the Technology, Media and Telecommunications Advisory Group in London, one of Lazard’s most active teams in the UK. Mr. Kapadia has had a wide range of corporate finance experience including providing advice to many of the UK's largest companies and private equity sponsors.
Mr. Rucker has served as CEO of Lazard’s Investment Banking business in the UK for the past 15 years. He began his investment banking career at Lazard in 1987. As Chairman, he will continue to work closely with Mr. Kapadia and the UK Investment Banking team, focusing in particular on key client relationships and growth initiatives.
Mr. Norman, a Senior Adviser for Lazard Investment Banking in the UK since 2003, has served as Chairman of Lazard UK Investment Banking since 2013. He was appointed Chairman of Marks & Spencer in October 2017.
Lazard in London is a principal office of the firm’s global network. It has been a major presence in London's financial center since 1877, and added institutional asset management services in 1953. Located in the heart of Mayfair, it is one of Lazard's largest offices, with senior professionals representing all of Lazard's advisory services.
Lazard’s UK Investment Banking business has advised or continues to advise on a number of significant transactions. These include advising Blackstone, KIRKBI and the Canada Pension Plan Investment Board on its acquisition of Merlin Entertainments; Saputo on its acquisition of Dairy Crest; Takeaway.com on its acquisition of JustEat, PLC; WPP on the sale of 60% of Kantar to Bain Capital; Smith & Nephew on its acquisition of Osiris Therapeutic; Daily Mail Trust Group on the sale of its shares in Euromoney PLC; and Merck on its global alliance with GSK.
About Lazard
Lazard, one of the world’s preeminent financial advisory and asset management firms, operates from 43 cities across 27 countries in North America, Europe, Asia, Australia, Central and South America. With origins dating to 1848, the firm provides advice on mergers and acquisitions, strategic matters, restructuring and capital structure, capital raising and corporate finance, as well as asset management services to corporations, partnerships, institutions, governments and individuals. For more information about Lazard, please visit www.lazard.com. Follow Lazard at @Lazard.
LAZ-FAPE
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005898/en/
Contact information
Media contacts:
Jenna Ward, +44 21 7187 2305
jenna.ward@lazard.com
Judi Frost Mackey, +1 212 632 1428
judi.mackey@lazard.com
Investor contact:
Alexandra Deignan, +1 212 632 6886
alexandra.deignan@lazard.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom